Laura Prendergast
Stock Analyst at Stifel Nicolaus
(4.34)
# 1,322
Out of 5,070 analysts
88
Total ratings
44.3%
Success rate
19.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Initiated Coverage: Buy | $48 | $35.36 | +35.75% | 1 | Oct 13, 2026 | |
| IMTX Immatics | Initiated Coverage: Buy | $15 | $7.51 | +99.73% | 1 | Oct 13, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | n/a | $196.55 | - | 24 | Oct 8, 2026 | |
| FHTX Foghorn Therapeutics | Reiterated: Buy | $12 → $5 | $2.01 | +148.76% | 8 | Oct 1, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $48 → $30 | $7.25 | +313.79% | 2 | Sep 14, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterated: Buy | $23 → $15 | $2.72 | +451.47% | 5 | Sep 9, 2026 | |
| ERAS Erasca | Reiterated: Buy | $30 | $14.62 | +105.20% | 12 | Aug 17, 2026 | |
| STRO Sutro Biopharma | Reiterated: Buy | $48 | $11.54 | +315.94% | 2 | Aug 17, 2026 | |
| TNGX Tango Therapeutics | Reiterated: Buy | $40 | $25.25 | +58.42% | 10 | Aug 17, 2026 | |
| BDTX Black Diamond Therapeutics | Reiterated: Buy | $8 | $2.07 | +286.47% | 7 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $13.78 | +1.60% | 2 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $31.24 | +44.05% | 9 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $11.08 | n/a | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $8.54 | n/a | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 | $1.74 | n/a | 1 | Aug 14, 2024 |
IDEAYA Biosciences
Oct 13, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $35.36
Upside: +35.75%
Immatics
Oct 13, 2026
Initiated Coverage: Buy
Price Target: $15
Current: $7.51
Upside: +99.73%
Revolution Medicines
Oct 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $196.55
Upside: -
Foghorn Therapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: $12 → $5
Current: $2.01
Upside: +148.76%
Olema Pharmaceuticals
Sep 14, 2026
Reiterated: Buy
Price Target: $48 → $30
Current: $7.25
Upside: +313.79%
BridgeBio Oncology Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $23 → $15
Current: $2.72
Upside: +451.47%
Erasca
Aug 17, 2026
Reiterated: Buy
Price Target: $30
Current: $14.62
Upside: +105.20%
Sutro Biopharma
Aug 17, 2026
Reiterated: Buy
Price Target: $48
Current: $11.54
Upside: +315.94%
Tango Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $40
Current: $25.25
Upside: +58.42%
Black Diamond Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $8
Current: $2.07
Upside: +286.47%
Aug 4, 2026
Reiterated: Buy
Price Target: $14
Current: $13.78
Upside: +1.60%
Jun 15, 2026
Reiterated: Buy
Price Target: $45
Current: $31.24
Upside: +44.05%
Jul 29, 2025
Reiterated: Buy
Price Target: $12
Current: $11.08
Upside: n/a
Feb 13, 2025
Reiterated: Buy
Price Target: $4
Current: $8.54
Upside: n/a
Aug 14, 2024
Upgraded: Buy
Price Target: $16
Current: $1.74
Upside: n/a